By using this site, you agree to the Privacy Policy and Terms of Use.
Accept
GMJ NewsGMJ NewsGMJ News
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Notification Show More
Font ResizerAa
GMJ NewsGMJ News
Font ResizerAa
  • Latest News
    • GMJ Briefs
  • Podcast & Media
    • Podcast Episodes
    • GMJ Audio
    • GMJ Videos
  • Research Digest
    • New Studies
    • Georgian Research
    • Data & Numbers
  • Policy & Systems
    • Health Policy
    • Quality & Safety
    • Migration & Health
    • Global Health
  • Practice
    • Clinical Updates
    • Case Discussions
    • Pharmacy & Prescribing
    • Ingredients A-Z
  • Perspectives
    • Editorial
    • Explainers
    • Voices
    • Letters
  • GMJ Articles
    • Vol. 1 Issue 2 (2026)
    • Vol. 1 Issue 1 (2026)
    • Pre-Launch Articles (2025)
  • Read the Journal →
  • About GMJ News
Follow US
GMJ News > Drugs A-Z > General > Solifenacin

Solifenacin

GMJ
Last updated: 02/06/2026 14:30
By
Prof. Giorgi Pkhakadze
Share
5 Min Read
SHARE
3 min read|615 words

Solifenacin: Uses, Side Effects, and Dosage Information

What is Solifenacin?

Solifenacin is an antimuscarinic medication that belongs to a class of drugs known as anticholinergics or muscarinic receptor antagonists. It is primarily prescribed to treat overactive bladder symptoms, including urgent need to urinate, frequent urination, and urinary incontinence. This prescription medication works by relaxing the bladder muscles to improve bladder control and reduce uncomfortable urinary symptoms.

Uses

Solifenacin is approved for several urological conditions:

  • Overactive bladder syndrome: The primary indication for treating symptoms of urgency, frequency, and urge incontinence in adults
  • Urinary urgency: Helps reduce the sudden, compelling need to urinate that is difficult to defer
  • Urinary frequency: Decreases the number of times patients need to urinate during the day and night
  • Urge incontinence: Reduces involuntary leakage of urine associated with a sudden strong desire to urinate
  • Neurogenic detrusor overactivity: Used in pediatric patients aged 2 years and older with neurological conditions affecting bladder function

How it works

Solifenacin works by blocking muscarinic receptors, specifically the M3 subtype, in the bladder muscle (detrusor muscle). By inhibiting these receptors, the medication prevents acetylcholine from binding and causing involuntary bladder contractions. This action allows the bladder to store more urine and reduces the frequency and urgency of urination, providing better bladder control for patients with overactive bladder symptoms.

Side effects

Common side effects include:

Submit Your Paper
GMJ_Submit_Banner
  • Dry mouth
  • Constipation
  • Blurred vision
  • Dizziness
  • Drowsiness
  • Nausea
  • Abdominal pain
  • Headache

Serious side effects to watch for:

  • Severe constipation or inability to empty bowels
  • Inability to urinate or empty the bladder completely
  • Severe allergic reactions including swelling of face, lips, or throat
  • Signs of heat stroke due to decreased sweating
  • Severe abdominal pain or bloating

Warnings and precautions

  • Bladder outlet obstruction: Should not be used in patients with urinary retention or gastric retention, or in those at risk for these conditions
  • Kidney and liver impairment: Dosage adjustments are necessary for patients with moderate to severe kidney or liver problems; not recommended for severe impairment
  • Pregnancy and breastfeeding: Should only be used during pregnancy if the potential benefit justifies the risk; caution advised during breastfeeding
  • Narrow-angle glaucoma: Contraindicated in patients with uncontrolled narrow-angle glaucoma due to risk of increased eye pressure
  • Heat-related illness: May cause decreased sweating and increased body temperature, particularly in hot environments or during physical activity

Interactions

Several medications and substances can interact with solifenacin:

  • Ketoconazole and other strong CYP3A4 inhibitors: Can increase solifenacin levels, requiring dose reduction
  • Other anticholinergic medications: May increase the risk of anticholinergic side effects like dry mouth and constipation
  • Digoxin: Solifenacin may increase digoxin absorption and blood levels
  • Medications that prolong QT interval: Combined use may increase risk of heart rhythm abnormalities
  • Potent CYP3A4 inducers: May decrease solifenacin effectiveness by reducing blood levels
  • Medications for glaucoma: Anticholinergic effects may counteract glaucoma treatments
  • Metformin: Solifenacin may affect metformin elimination through the kidneys
  • Alcohol: May enhance drowsiness and dizziness effects

Check interactions with the GMJ Interaction Checker

Dosage

For adults with overactive bladder, the typical starting dose is 5 mg once daily taken orally. Based on individual response and tolerability, the dose may be increased to 10 mg once daily. For patients with moderate kidney impairment or those taking strong CYP3A4 inhibitors, the maximum recommended dose is 5 mg daily. Solifenacin can be taken with or without food, and tablets should be swallowed whole with liquid. Dosage adjustments should always be made under medical supervision, and patients should not exceed the prescribed amount or stop taking the medication without consulting their healthcare provider.

Sources: FDA DailyMed drug labels (public domain), BNF, WHO Essential Medicines List. This article is for informational purposes only and does not constitute medical advice. Always consult your healthcare provider before starting or stopping any medication.

Cite this page

GMJ News Desk. "Solifenacin." GMJ News — Georgian Medical Journal, 2 June 2026. https://news.gmj.ge/drug/solifenacin/

CC BY 4.0This work is licensed under Creative Commons Attribution 4.0 International (CC BY 4.0). You are free to share and adapt this content with attribution to GMJ News (news.gmj.ge).

Was this article helpful?

Share This Article
Facebook LinkedIn Bluesky Copy Link Print
GMJ
ByProf. Giorgi Pkhakadze
Follow:
Prof. Giorgi Pkhakadze, MD, MPH, PhD, is Editor-in-Chief of the Georgian Medical Journal and Chair of the Public Health Institute of Georgia (PHIG). He is Professor and Head of the Department of Social and Behavioural Sciences at David Tvildiani Medical University, and Secretary/Treasurer of the UEMS Section of Public Health. ORCID: 0000-0001-7609-4515.

Submit Your Paper →

Georgia's peer-reviewed open-access medical journal. No APC until January 2027.
Submit Manuscript →
Revolution Medicines Ships Experimental Pancreatic Cancer Drug Under Early Access

Revolution Medicines begins expanded access program for daraxonrasib targeting KRAS G12C mutations.…

NHS Patient Watchdog Abolition Sparks Concerns Over Health Service Accountability

Local councils warn that government plans to abolish NHS patient watchdogs will…

DNA Test Could Spare 6,600 Breast Cancer Patients From Unnecessary Chemotherapy

New genetic testing could spare 6,600 UK breast cancer patients annually from…

Submit Your Paper to GMJ

No APC until January 2027.
Submit Manuscript →

You Might Also Like

Amikacin

By
Prof. Giorgi Pkhakadze
02/06/2026

Leflunomide

By
Prof. Giorgi Pkhakadze
02/06/2026

Amphetamine

By
Prof. Giorgi Pkhakadze
02/06/2026

Turmeric/Curcumin

By
Prof. Giorgi Pkhakadze
02/06/2026
Facebook Twitter Youtube Instagram
Company
  • Privacy Policy
  • Contact US
  • GMJ Journal
  • Submit Manuscript
  • Editorial Team
  • Register at GMJ
  • Terms of Use

Subscribe to GMJ News — Click here

Join Community
© 2026 Georgian Medical Journal (GMJ). Published by the Public Health Institute of Georgia (PHIG). All rights reserved.
Welcome Back!

Sign in to your account

Username or Email Address
Password

Lost your password?

Not a member? Sign Up